• Current CDC guidelines continue to recommend COVID-19 vaccines for all individuals aged 6 months and older, including pregnant women.
  • The Advisory Committee on Immunization Practices is evaluating potential adjustments for the 2025-2026 season, with no changes yet implemented.
  • High-risk groups, including immunocompromised individuals and adults over 65, remain prioritized for multiple doses.

CDC Vaccine Policy Under Review

The Centers for Disease Control and Prevention (CDC) has not altered its COVID-19 vaccination recommendations for children or pregnant women, contrary to some recent speculation. The agency's current guidelines, established in late 2024, remain in effect while its advisory committee evaluates potential updates for the upcoming 2025-2026 season.

According to sources familiar with the deliberations, the Advisory Committee on Immunization Practices (ACIP) is considering several policy options. These include maintaining universal recommendations, shifting to risk-based guidelines, or implementing a hybrid approach. No final decisions have been made, and any changes wouldn't take effect until later this year.

Current Recommendations Stand

The existing framework recommends vaccination for all individuals aged six months and older, with specific guidance for vulnerable populations. Adults 65+ and immunocompromised individuals are advised to receive two doses of the 2024-2025 formulation. Additional doses may be considered for high-risk patients through shared decision-making with healthcare providers.

Pregnant women continue to be strongly encouraged to vaccinate, given their elevated risk of severe outcomes and the added benefit of protecting newborns. 'The data clearly shows vaccination during pregnancy provides protection for both mother and baby,' noted one committee member who asked not to be identified as discussions are ongoing.

Looking Ahead

Market analysts suggest pharmaceutical companies are closely monitoring these deliberations, as any policy shift could impact vaccine demand. Moderna and Pfizer shares showed minimal movement following the clarification of current guidelines.

The CDC declined to comment on the ongoing review process but confirmed no immediate changes to recommendations are planned. A formal announcement regarding 2025-2026 guidelines is expected later this summer following thorough data review and public health evaluation.